Flagship Ventures — Full Portfolio
6 tracked investments · listed companies and verified rows first
Agios is a biopharmaceutical company developing therapies for rare diseases, with a primary focus on hemolytic anemias including pyruvate kinase deficiency, thalassemia, and sickle cell disease.
BiotechHealthtechMedical Devices
Lewis C. Cantley, Ph.D.(Founder)Tak Mak, Ph.D.(Founder)Craig B. Thompson, M.D.(Founder)Brian Goff(Chief Executive Officer)in
Co-investorsARCH Venture PartnersThird Rock VenturesSamsara BioCapital
BiotechCambridge, US
Robert Connelly(Executive Officer, Director)Garry Menzel(Executive Officer)Jeff Moore(Executive Officer)
BoardJohn Mendlein(Director)David Berry(Director)inNoubar Afeyan(Director)in
Co-investorsFidelity InvestmentsFlagship Pioneering
BiotechCambridge, US
Torben Straight Nissen(Executive Officer, Director)inJoanne Protano(Executive Officer)inDavid Epstein(Director)Harvey F. Lodish(Director)Michael Rosenblatt(Director)Roger Pomerantz(Director)
Co-investorsFlagship PioneeringKendall Capital Partners
BiotechCambridge, US
HOWARD BERNSTEIN(Executive Officer)HOWARD WEISMAN(Executive Officer, Director)
BoardALAN CRANE(Director)ROBERT LANGER(Director)ANUPENDRA SHARMA(Director)HARRY WILCOX(Director)
Co-investorsFlagship PioneeringNewpath PartnersPolaris Partners
Syros Pharmaceuticals is a Massachusetts gene-control biotech developing small molecules that regulate disease gene expression.
Co-investorsAisling CapitalARCH Venture PartnersQuan CapitalREDMILE
BiotechWatertown, US
Guy Macdonald(Director)inLarry Edwards(Executive Officer, Director)inMaria Stahl(Executive Officer)inChristopher Watt(Executive Officer)
BoardL. Patrick Gage(Director)Keith Maher(Director)
Co-investorsBay City CapitalF-Prime CapitalExcel Venture ManagementMediphase Venture Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.